The MARK2 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-mediated loss-of-function model in which the serine/threonine kinase MARK2 gene has been disrupted in the Raji B lymphocyte cell line. This product is supplied as a polyclonal knockout cell population, providing a heterogeneous pool of edited cells suitable for functional studies without clonal isolation. The polyclonal format enables researchers to assess overall population-level phenotypic changes resulting from MARK2 ablation while mitigating clone-specific artifacts. This model system is designed for investigations into cell polarity, signal transduction, and lymphoma biology, offering a versatile tool for both mechanistic and translational research applications.
The parental Raji cell line was originally derived from a Burkitt’s lymphoma patient and is characterized by Epstein-Barr virus positivity and a lymphoblastoid phenotype. Raji cells grow in suspension culture and are extensively used as a model for B-cell malignancies, immune cell signaling, and hematologic cancer biology. Their transformed nature and constitutive activation of growth-promoting pathways make them particularly well-suited for dissecting oncogenic mechanisms. By introducing targeted disruption of MARK2 into this background, the cells facilitate the study of kinase-dependent processes in a disease-relevant context.
MARK2 encodes a serine/threonine-protein kinase that phosphorylates microtubule-associated proteins, including Tau (MAPT), MAP2, and MAP4, thereby promoting microtubule destabilization and regulating cell polarity. In the broader signaling network, MARK2 is activated by upstream kinases LKB1 (STK11) and CaMKK, and functions downstream of energy-sensing pathways mediated by AMPK and PI3K/AKT signaling. It interacts with 14-3-3 proteins, PAK5, and the polarity complex components PARD3 and PARD6. Through these interactions, MARK2 contributes to the coordination of AMPK/mTOR, Wnt, and Hippo pathway outputs, linking metabolic cues to cytoskeletal organization and cell growth control.
In Raji B cells, MARK2 knockout is expected to profoundly affect microtubule dynamics and cell polarity, potentially disrupting processes essential for lymphoma cell proliferation, migration, and survival. Given the role of MARK2 in energy homeostasis and its integration with the AMPK/mTOR axis, loss of this kinase may alter the cells’ response to nutrient stress and therapeutic agents. Furthermore, dysregulation of Wnt signaling downstream of MARK2 could impact ??-catenin-dependent transcription and contribute to altered growth characteristics. This model therefore provides a valuable platform for exploring how polarity kinase signaling influences Burkitt’s lymphoma pathogenesis.
This polyclonal knockout cell product is suitable for a range of experimental applications. Researchers can employ Western blotting to confirm MARK2 ablation and assess phosphorylation of downstream targets such as Tau, or use immunofluorescence to visualize microtubule organization. Flow cytometry enables analysis of cell cycle and apoptosis, while proliferation and migration assays (e.g., MTT, transwell) help evaluate functional consequences. Transcriptomic profiling via RNA-seq can uncover global gene expression changes, and co-immunoprecipitation can elucidate altered protein interactions. These cells support drug sensitivity testing for kinase inhibitors and mechanistic dissection of AMPK/mTOR and Wnt pathways in lymphoma. For further details or technical support, please contact Ascent Research.
